A Phase 2 interventional study of IDP-126 Gel and IDP-126 Vehicle Gel in Acne Vulgaris, sponsored by Bausch Health Americas, Inc.. Completed at 42 sites in 3 countries. Open to participants aged 12 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Acne Vulgaris by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Bausch Health Companies Inc..
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., this one is the 10th largest by enrollment of the 35 interventional ones that give a count, is the only one that started in 2021, is one of 10 in phase 2, and was the 34th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →1 of the 36 studies in Acne Vulgaris by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
By country, each count listing its studies:
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 686 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 247 across the 35 interventional studies, 200 across the 1 observational. Of the 31 that completed or were terminated, 19 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison with Epiduo® Forte gel and IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12. To be eligible for the study, subjects must be at least 12 years of age and have a clinical diagnosis of moderate to severe acne (defined as an Evaluator's Global Severity Score [EGSS] of 3 or 4), presenting with 30-100 inflammatory facial lesions (papules, pustules, and nodules), 35-150 non-inflammatory facial lesions (open and closed comedones), and ≤ 2 facial nodules.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IDP-126 Gel (clindamycin phosphate 1.2%, BPO 3.1%, and adapalene 0.15%), applied topically to the face once daily for 12 weeks
Drug: IDP-126 Gel
IDP-126 Vehicle Gel applied once daily for 12 weeks
Drug: IDP-126 Vehicle Gel
Epiduo® Forte Gel (adapalene 0.3%/ 2.5% BPO) applied once daily for 12 weeks
Drug: Epiduo® Forte Gel
Gel applied to face once daily in the evening.
Also known as: IDP-126
Gel applied to face once daily in the evening.
Also known as: Vehicle
Gel applied to face once daily in the evening.
Also known as: Epiduo® Forte
Absolute Change From Baseline to Week 12 in Lesion Counts.
Inflammatory and non-inflammatory lesion counts were collected starting from the Baseline Visit.
Time frame: Baseline to Week 12
Percentage of Subjects Who Achieve at Least a Two-grade Reduction From Baseline and Are "Clear" or "Almost Clear" at Week 12 in the Evaluator's Global Severity Score.
The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
Time frame: Baseline to Week 12
| Milestone | IDP-126 Gel | IDP-126 Vehicle Gel | Epiduo® Forte Gel |
|---|---|---|---|
| Started | 230 | 228 | 228 |
| Completed | 201 | 196 | 182 |
| Not completed | 29 | 32 | 46 |
Inflammatory and non-inflammatory lesion counts were collected starting from the Baseline Visit.
| lesion counts | IDP-126 Gel | IDP-126 Vehicle Gel | Epiduo® Forte Gel |
|---|---|---|---|
| Absolute Change From Baseline to Week 12 in Lesion Counts. | -29.9 ± 11.43 | -19.7 ± 13.11 | -27.9 ± 12.16 |
The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
| participants | IDP-126 Gel | IDP-126 Vehicle Gel | Epiduo® Forte Gel |
|---|---|---|---|
| Percentage of Subjects Who Achieve at Least a Two-grade Reduction From Baseline and Are "Clear" or "Almost Clear" at Week 12 in the Evaluator's Global Severity Score. | 118 | 41 | 74 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDP-126 Gel | 0/230 (0%) | 1/230 (0.4%) | 23/230 (10%) |
| IDP-126 Vehicle Gel | 0/228 (0%) | 0/228 (0%) | 0/228 (0%) |
| Epiduo® Forte Gel | 0/226 (0%) | 0/226 (0%) | 16/226 (7.1%) |
| Event | IDP-126 Gel | IDP-126 Vehicle Gel | Epiduo® Forte Gel |
|---|---|---|---|
| Motor Vehicle AccidentInjury, poisoning and procedural complications | 1/230 | 0/228 | 0/226 |
| Event | IDP-126 Gel | IDP-126 Vehicle Gel | Epiduo® Forte Gel |
|---|---|---|---|
| Application Site PainGeneral disorders | 23/230 | 0/228 | 16/226 |
| Age, Continuous(years) | IDP-126 Gel | IDP-126 Vehicle Gel | Epiduo® Forte Gel | Total |
|---|---|---|---|---|
| Median | 17.5 (12 to 56) | 17 (12 to 51) | 18 (12 to 51) | 17 (12 to 56) |
| Sex: Female, Male(Participants) | IDP-126 Gel | IDP-126 Vehicle Gel | Epiduo® Forte Gel | Total |
|---|---|---|---|---|
| Female | 140 | 131 | 135 | 406 |
| Male | 90 | 97 | 91 | 278 |
| Race (NIH/OMB)(Participants) | IDP-126 Gel | IDP-126 Vehicle Gel | Epiduo® Forte Gel | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 0 | 3 |
| Asian | 16 | 27 | 19 | 62 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 24 | 28 | 26 | 78 |
| White | 179 | 160 | 165 | 504 |
| More than one race | 7 | 4 | 11 | 22 |
| Unknown or Not Reported | 4 | 6 | 5 | 15 |
| Baseline Evaluator's Global Severity Score(Participants) | IDP-126 Gel | IDP-126 Vehicle Gel | Epiduo® Forte Gel | Total |
|---|---|---|---|---|
| Moderate | 201 | 204 | 198 | 603 |
| Severe | 29 | 24 | 28 | 81 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2021 to primary completion in Sep 2022, 15 months.
Results were first posted in Oct 2025, 3 years 1 month after primary completion. A results delay was requested in Aug 2023.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 15 months is above that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IDP-126
Bausch Health Americas, Inc. →